The efficacy of acute electroconvulsive therapy in atypical depression

Journal of Clinical Psychiatry

Volumn 69, Issue 3, 2008, Pages 406-411

  Husain, Mustafa M ^a   McClintock, Shawn M ^a,b   Rush, A John ^a   Knapp, Rebecca G ^c   Fink, Max ^e   Rummans, Teresa A ^f   Rasmussen, Keith ^f   Claassen, Cynthia ^a   Petrides, Georgios ^g   Biggs, Melanie M ^a   Mueller, Martina ^d   Sampson, Shirlene ^f   Bailine, Samuel H ^e   Lisanby, Sarah H ^b   Kellner, Charles H ^g  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e ZUCKER HILLSIDE HOSPITAL   (United States)

^f MAYO CLINIC   (United States)

^g RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; LITHIUM CARBONATE; NORTRIPTYLINE;

ADULT; ARTICLE; ATYPICAL DEPRESSION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; STRUCTURED INTERVIEW;

EID: 42249101235     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0310     Document Type: Article

References (40)

1. Sargant W. The treatment of anxiety states and atypical depressions by the monoamine oxidase inhibitor drugs. J Neuropsychiatr 1962;3(suppl 1): S96-S103
2. West ED, Dally PJ. Effects of iproniazid in depressive syndromes. BMJ 1959;1:1491-1494
3. Sotsky SM, Simmens SJ. Pharmacotherapy response and diagnostic validity in atypical depression. J Affect Disord 1999;54:237-247
4. Lam RW, Stewart JN. The validity of atypical depression in DSM-IV. Compr Psychiatry 1996;37:375-383
5. Stewart JW, McGrath PJ, Rabkin JG, et al. Atypical depression: a valid clinical entity? Psychiatr Clin North Am 1993;16:479-495
6. Angst J, Gamma A, Sellaro R, et al. Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord 2002;72:125-138
7. Horwath E, Johnson J, Weissman MM, et al. The validity of major depression with atypical features based on a community study. J Affect Disord 1992;26:117-125
8. Levitan RD, Lesage A, Parikh SV, et al. Reversed neurovegetative symptoms of depression: a community study of Ontario. Am J Psychiatry 1997;154:934-940
9. Sullivan PF, Kessler RC, Kendler KS. Latent class analysis of lifetime depressive symptoms in the National Comorbidity Survey. Am J Psychiatry 1998;155:1398-1406
10. Novick JS, Stewart JW, Wisniewski SR, et al. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry 2005;66:1002-1011
11. American Psychiatric Association. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, Second Edition. Washington, DC: American Psychiatric Association; 2001
12. Greenberg RM, Kellner CH. Electroconvulsive therapy: a selected review. Am J Geriatr Psychiatry 2005;13:268-281
13. Husain MM, Rush AJ, Fink M, et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry 2004;65:485-491
14. Sackeim HA, Decina P, Prohovnik I, et al. Seizure threshold in electroconvulsive therapy: effects of sex, age, electrode placement, and number of treatments. Arch Gen Psychiatry 1987;44:355-360
15. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006;63:1337-1344
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
17. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
18. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, version 2.0). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1997
19. Kellner CH, Fink M, Knapp R, et al. Relief of expressed suicidal intent by ECT: a Consortium for Research in ECT study. Am J Psychiatry 2005;162:977-982
20. O'Connor MK, Knapp R, Husain M, et al. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. report. Am J Geriatr Psychiatry 2001;9(4):382-390
21. Beale MD, Kellner CH, Pritchett JT, et al. Stimulus dose-titration in ECT: a 2-year clinical experience. Convuls Ther 1994;10:171-176
22. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996;26:477-486
23. Rush AJ, Carmody TJ, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000;9:45-59
24. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004;34:73-82
25. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res 1990;31:287-296
26. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420-427
27. Breakey WR, Dunn GJ. Racial disparity in the use of ECT for affective disorders. Am J Psychiatry 2004;161:1635-1641
28. Olfson M, Marcus S, Sackeim HA, et al. Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry 1998;155:22-29
29. Kennedy SH, Eisfeld BS, Meyer JH, et al. Antidepressants in clinical practice: limitations of assessment methods and drug response. Hum Psychopharmacol 2001;16:105-114
30. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-137
31. Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988;145:306-311
32. Posternak MA, Zimmerman M. Partial validation of the atypical features subtype of major depressive disorder. Arch Gen Psychiatry 2002;59:70-76
33. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
34. Matza LS, Revicki DA, Davidson JR, et al. Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. Arch Gen Psychiatry 2003;60:817-826
35. Stewart JW, Quitkin FM, McGrath PJ, et al. Defining the boundaries of atypical depression: evidence from the HPA axis supports course of illness distinctions. J Affect Disord 2005;86:161-167
36. Stewart JW, McGrath PJ, Quitkin FM, et al. Atypical depression: current status and relevance to melancholia. Acta Psychiatr Scand Suppl 2007;433:58-71
37. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT 2001;17:244-253
38. Parker G, Roy K, Mitchell P, et al. Atypical depression: a reappraisal. Am J Psychiatry 2002;159:1470-1479
39. Jarrett RB, Schaffer M, McIntire D, et al. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:431-437
40. Fava M, Uebelacker LA, Alpert JE, et al. Major depressive subtypes and treatment response. Biol Psychiatry 1997;42:568-576